NASDAQ: ALVR - AlloVir, Inc.

Yield per half year: +14.3%
Sector: Healthcare

Share chart AlloVir, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Allovir, Inc., компания, занимающаяся клеточной терапией на клинической стадии, занимается исследованиями и разработкой готовых аллогенных методов лечения поливирусными Т-клетками (VST) для предотвращения и лечения разрушительных вирусно-ассоциированных заболеваний. Ведущим продуктом компании является Viralym-M, аллогенная, готовая к применению VST-терапия для лечения вируса ВК, цитомегаловируса, аденовируса, вируса Эпштейна-Барра и вируса герпеса человека 6.

More details
Его кандидаты для доклинической и клинической разработки включают ALVR106 для респираторного синцитиальный вирус, вирус гриппа, вирус парагриппа и метапневмовирус человека; ALVR109 для лечения SARS-CoV-2 и COVID-19; ALVR107 для лечения гепатита B; и ALVR108 для лечения вируса герпеса-8 человека, включая саркому Капоши, первичную выпотную лимфому и многоцентровую болезнь Кастлемана. Ранее компания была известна как ViraCyte, Inc. и сменила название на Allovir, Inc. в мае 2019 года. Компания Allovir, Inc. была основана в 2013 году и находится в Кембридже, штат Массачусетс.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

P/BV 2.82
EV/EBITDA 1.85
Цена ао 0.8
P/S 0
EBITDA -0.0267
Сайт http://www.allovir.com
Число акций ао 0.10406 млрд
Выручка 0.000165
Див.доход ао 0
ISIN US0198181036
Валюта usd
IPO date 2020-07-30
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +3.4% (0.8124)
Change price per week: +6.94% (0.7855)
Change price per month: +12.15% (0.749)
Change price per 3 month: +6.33% (0.79)
Change price per half year: +14.3% (0.7349)
Change price per year: -50.59% (1.7)
Change price per 3 year: -96.58% (24.54)
Change price per year to date: -44.74% (1.52)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.5361 10
P/E 0 0
EV/EBITDA -0.0854 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -99.8 0
ROE, % -130.62 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1516 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % -85 0
Yield Ebitda, % 577.65 10
Yield EPS, % 267.02 10
Total: 8
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
22.10.2024 23.10.2024 Miller Edward
General Counsel		 Sale 0.77 590 766 0 0 link
22.10.2024 23.10.2024 Hagen Brett R
Chief Accounting Officer		 Sale 0.77 374 486 0 0 link
22.10.2024 22.10.2024 Sinha Vikas
Owner		 Purchase 0.77 1 449 1882 0 0 link
22.10.2024 22.10.2024 Miller Edward
Officer		 Purchase 0.77 590 766 0 0 link
22.10.2024 22.10.2024 Hagen Brett R
Officer		 Purchase 0.77 374 486 0 0 link
21.10.2024 23.10.2024 Miller Edward
General Counsel		 Sale 0.78 495 635 0 0 link
21.10.2024 23.10.2024 Hagen Brett R
Chief Accounting Officer		 Sale 0.78 374 479 0 0 link
21.10.2024 23.10.2024 Brainard Diana
Chief Executive Officer		 Sale 0.78 7 607 9752 0 -0.01 link
21.10.2024 21.10.2024 Brainard Diana
Officer		 Purchase 0.78 7 607 9752 0 0.01 link
21.10.2024 21.10.2024 Miller Edward
Officer		 Purchase 0.78 495 635 0 0 link
21.10.2024 21.10.2024 Sinha Vikas
Owner		 Purchase 0.78 1 206 1546 0 0 link
21.10.2024 21.10.2024 Hagen Brett R
Officer		 Purchase 0.78 374 479 0 0 link
19.08.2024 20.08.2024 Brainard Diana
Chief Executive Officer		 Sale 0.76 2 349 3091 0 0 link
19.08.2024 20.08.2024 Sinha Vikas
See Remarks		 Sale 0.76 2 401 3159 0 0 link
19.08.2024 20.08.2024 Hagen Brett R
Chief Accounting Officer		 Sale 0.76 413 544 0 0 link
19.08.2024 20.08.2024 Miller Edward
General Counsel		 Sale 0.76 321 422 0 0 link
05.08.2024 06.08.2024 Miller Edward
Officer		 Purchase 0.73 1 696 2323 0 0 link
05.08.2024 06.08.2024 Hagen Brett R
Officer		 Purchase 0.73 1 235 1692 0 0 link
05.08.2024 06.08.2024 Brainard Diana
Officer		 Purchase 0.73 7 918 10847 0 0.02 link
05.08.2024 06.08.2024 Sinha Vikas
Owner		 Purchase 0.73 3 833 5251 0 0.01 link
22.07.2024 23.07.2024 Miller Edward
General Counsel		 Sale 0.74 560 757 0 0 link
22.07.2024 23.07.2024 Sinha Vikas
See Remarks		 Sale 0.74 1 375 1858 0 0 link
22.07.2024 23.07.2024 Hagen Brett R
Chief Accounting Officer		 Sale 0.74 356 481 0 0 link
19.07.2024 23.07.2024 Miller Edward
General Counsel		 Sale 0.75 476 634 0 0 link
19.07.2024 23.07.2024 Sinha Vikas
See Remarks		 Sale 0.75 1 157 1542 0 0 link
19.07.2024 23.07.2024 Brainard Diana
Chief Executive Officer		 Sale 0.75 7 298 9731 0 -0.01 link
19.07.2024 23.07.2024 Hagen Brett R
Chief Accounting Officer		 Sale 0.75 359 479 0 0 link
22.04.2024 23.04.2024 Sinha Vikas
See Remarks		 Sale 0.75 1 393 1857 0 0 link
22.04.2024 23.04.2024 Miller Edward
General Counsel		 Sale 0.75 568 757 0 0 link
19.04.2024 23.04.2024 Sinha Vikas
See Remarks		 Sale 0.75 1 141 1521 0 0 link
19.04.2024 23.04.2024 Brainard Diana
Chief Executive Officer		 Sale 0.75 7 201 9601 0 -0.01 link
02.04.2024 04.04.2024 Sinha Vikas
See Remarks		 Sale 0.77 681 885 0 0 link
02.04.2024 04.04.2024 Hagen Brett R
Chief Accounting Officer		 Sale 0.77 216 281 0 0 link
08.02.2024 09.02.2024 Hagen Brett R
Chief Accounting Officer		 Sale 0.67 7 471 11150 0 -0.02 link
20.01.2023 23.01.2023 Hagen Brett R
Chief Accounting Officer		 Sale 5.14 1 737 338 0 0 link
20.01.2023 23.01.2023 Miller Edward
General Counsel		 Sale 5.14 2 781 541 0 0 link
20.01.2023 23.01.2023 Sinha Vikas
See Remarks		 Sale 5.14 7 330 1426 0 0 link
19.01.2023 23.01.2023 Brainard Diana
Chief Executive Officer		 Sale 5.08 174 930 34435 0 -0.05 link
19.01.2023 23.01.2023 Hagen Brett R
Chief Accounting Officer		 Sale 5.08 7 910 1557 0 0 link
19.01.2023 23.01.2023 Miller Edward
General Counsel		 Sale 5.08 10 323 2032 0 0 link
19.01.2023 23.01.2023 Sinha Vikas
See Remarks		 Sale 5.08 25 964 5111 0 -0.01 link
19.10.2022 21.10.2022 Hallal David
Director		 Sale 8.45 5 070 000 600000 0 -0.92 link
21.07.2022 21.07.2022 Hallal David
Director		 Sale 5.33 22 530 4227 0 -0.01 link
20.07.2022 21.07.2022 VAN BEEK JEROEN B
Chief Commercial Officer		 Sale 5.21 5 512 1058 0 0 link
20.07.2022 21.07.2022 Atillasoy Ercem
See Remarks		 Sale 5.21 2 933 563 0 0 link
20.07.2022 21.07.2022 Sinha Vikas
See Remarks		 Sale 5.21 7 461 1432 0 0 link
24.01.2022 25.01.2022 Hallal David
Director		 Sale 8.01 136 971 17100 0 -0.03 link

Institutions Volume Share, %
Artal Group S.A. 6597167 5.74
FMR, LLC 5692782 4.96
Millennium Management LLC 3904009 3.4
Wasatch Advisors LP 3784623 3.29
Blackrock Inc. 3526112 3.07
Vanguard Group Inc 2938605 2.56
Woodline Partners LP 2511004 2.19
Redmile Group, LLC 1907969 1.66
Geode Capital Management, LLC 1253238 1.09
American International Group, Inc. 1154193 1

ETF Share, % Profitability for 1 year, % Dividends, %
Schwab U.S. Small-Cap ETF 0.00124 -30.367553865653 1.51433



Head Job title Payment Year of birth
Mr. David L. Hallal Executive Chairman of the Board 254.38k 1966 (58 years)
Dr. Diana M. Brainard M.D. CEO & Director 978.99k 1972 (52 years)
Mr. Brett R. Hagen Chief Accounting Officer N/A 1973 (51 year)
Dr. Ann M. Leen Ph.D. Chief Scientific Officer N/A 1977 (47 years)
Mr. Vikas Sinha C.A., CPA, M.B.A. President, CFO & Director 536.21k 1963 (61 year)
Mr. Edward Miller J.D. General Counsel & Secretary 618.39k 1965 (59 years)
Ms. Cintia Piccina Pharm.D. Chief Commercial Officer N/A 1973 (51 year)

Address: United States, Cambridge, MA , 139 Main Street - open in Google maps, open in Yandex maps
Website: http://www.allovir.com